Sodium oxybate
Lumryz, Xyrem, Xywav (sodium oxybate) is a small molecule pharmaceutical. Sodium oxybate was first approved as Xyrem on 2002-07-17. It is used to treat cataplexy in the USA. It has been approved in Europe to treat cataplexy and narcolepsy.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lumryz | New Drug Application | 2025-07-03 |
| n/a | NDA authorized generic | 2022-10-04 |
| sodium oxybate | ANDA | 2025-05-19 |
| xyrem | New Drug Application | 2025-07-01 |
| xywav | New Drug Application | 2025-07-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SODIUM OXYBATE, LUMRYZ, AVADEL CNS | |||
| 2030-05-01 | ODE-431 | ||
| 2026-05-01 | NP | ||
CALCIUM OXYBATE / MAGNESIUM OXYBATE / POTASSIUM OXYBATE / SODIUM OXYBATE, XYWAV, JAZZ | |||
| 2028-08-12 | ODE-369 | ||
| 2027-07-21 | ODE-361 | ||
| 2024-08-12 | I-870 | ||
| 2023-07-21 | NP | ||
SODIUM OXYBATE, XYREM, JAZZ PHARMS | |||
| 2026-04-26 | PED | ||
| 2025-10-26 | ODE-231 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sodium Oxybate, Lumryz, Avadel Cns | |||
| 11583510 | 2042-02-07 | U-3578 | |
| 10925844 | 2040-02-28 | DP | |
| 10272062 | 2037-07-21 | DP | |
| 10736866 | 2037-07-21 | DP | |
| 10952986 | 2037-07-21 | U-3601 | |
| 10973795 | 2037-07-21 | DP | |
| 11000498 | 2037-07-21 | DP | U-3580 |
| 11052061 | 2037-07-21 | DP | |
| 11065224 | 2037-07-21 | DP | |
| 11400065 | 2037-07-21 | U-3579 | |
| 11504347 | 2037-07-21 | DP | |
| 11602512 | 2037-07-21 | U-3577 | |
| 11602513 | 2037-07-21 | U-3576 | |
| Calcium Oxybate / Magnesium Oxybate / Potassium Oxybate / Sodium Oxybate, Xywav, Jazz | |||
| 11426373 | 2037-09-19 | U-3432 | |
| 8772306 | 2033-03-15 | U-1532, U-3198 | |
| 9050302 | 2033-03-15 | U-1532 | |
| 9486426 | 2033-03-15 | U-1532 | |
| 10213400 | 2033-03-15 | U-2499 | |
| 10864181 | 2033-03-15 | U-1532, U-3017 | |
| 11253494 | 2033-03-15 | U-3323, U-3324 | |
| 8591922 | 2033-01-11 | DP | |
| 8901173 | 2033-01-11 | DP | |
| 9132107 | 2033-01-11 | DP | |
| 10195168 | 2033-01-11 | DP | |
| 10675258 | 2033-01-11 | U-2938 | |
| 11554102 | 2033-01-11 | DP | |
| Sodium Oxybate, Xyrem, Jazz Pharms | |||
| 7668730 | 2024-06-16 | U-1110 | |
ATC Codes
HCPCS
No data
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | 3 | 1 | 8 | 4 | 4 | 20 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | 2 | 2 | 5 | 3 | — | 11 |
| Sleepiness | D000077260 | — | R40.0 | 1 | 1 | 3 | 1 | — | 6 |
| Cataplexy | D002385 | — | — | 1 | — | 3 | 1 | — | 5 |
| Idiopathic hypersomnia | D020177 | — | G47.11 | — | 1 | 2 | 3 | — | 5 |
| Syndrome | D013577 | — | — | — | — | — | 5 | — | 5 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | — | 1 | — | 3 |
| Fatigue | D005221 | — | R53.83 | — | — | — | 3 | — | 3 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | — | 3 | — | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | 2 | — | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 1 | 4 | — | — | 5 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 4 | — | — | 5 |
| Dysphonia | D055154 | — | R49.0 | 1 | 2 | 1 | — | — | 3 |
| Tremor | D014202 | — | R25.1 | — | 3 | 1 | — | — | 3 |
| Hoarseness | D006685 | — | R49.0 | — | 2 | 1 | — | — | 2 |
| Cluster headache | D003027 | — | G44.00 | — | 1 | 1 | — | — | 2 |
| Sleep wake disorders | D012893 | — | G47 | — | — | 1 | — | — | 1 |
| Headache | D006261 | — | R51 | — | — | 1 | — | — | 1 |
| Bulimia | D002032 | — | F50.2 | — | 1 | 1 | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parasomnias | D020447 | — | G47.5 | — | 2 | — | — | — | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | 1 | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 2 | — | — | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | 1 | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | 1 | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | — | — | — | 1 |
| Hemiplegia | D006429 | — | G81.0 | 1 | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Ventilator weaning | D015300 | — | — | — | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Chemsex | D000099004 | — | — | 1 | — | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | — | — | — | — | 1 |
| Brain injuries | D001930 | — | S06.9 | 1 | — | — | — | — | 1 |
| Intrinsic sleep disorders | D020919 | — | F51.03 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Psychological trauma | D000067073 | — | — | — | — | — | — | 1 | 1 |
| Traumatic stress disorders | D040921 | — | — | — | — | — | — | 1 | 1 |
| Physiological stress | D013312 | — | — | — | — | — | — | 1 | 1 |
| Sleep deprivation | D012892 | — | F51.12 | — | — | — | — | 1 | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Kidney transplantation | D016030 | — | — | — | — | — | — | 1 | 1 |
| Hernia | D006547 | — | K40-K46 | — | — | — | — | 1 | 1 |
| Incisional hernia | D000069290 | — | K43.2 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sodium oxybate |
| INN | — |
| Description | Sodium oxybate, sold under the brand name Xyrem or Alcover among others, is a medication used to treat three symptoms of narcolepsy: sudden muscle weakness and excessive daytime sleepiness and alcohol dependence. It is used sometimes in France and Italy as an anesthetic given intravenously;: 15, 27–28  it is also approved and used in Italy and in Austria to treat alcohol dependence and alcohol withdrawal syndrome.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C([O-])CCCO.[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 502-85-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200682 |
| ChEBI ID | — |
| PubChem CID | 23663870 |
| DrugBank | DB09072 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xyrem – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Xywav – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,520 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lumryz, N/a, Sodium oxybate, Xyrem, Xywav
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
77,216 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use